SEC Form 4 · accession 0001209191-18-026607
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, COO
Period of report
Apr 25, 2018
Accepted (ET)
Apr 27, 2018 · 4:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 25, 2018 | M | 4,250 | $77.31 | A | 68,745 | D | |
| Common Stock | Apr 25, 2018 | M | 2,156 | $91.05 | A | 70,901 | D | |
| Common Stock | Apr 25, 2018 | M | 7,766 | $86.52 | A | 78,667 | D | |
| Common StockF2,F3 | Apr 25, 2018 | S | 19,478 | $154.98 | D | 59,189 | D | |
| Common StockF2,F4 | Apr 25, 2018 | S | 9,790 | $155.62 | D | 49,399 | D | |
| Common StockF2,F5 | Apr 25, 2018 | S | 2,700 | $156.78 | D | 46,699 | D | |
| Common Stock | Apr 26, 2018 | M | 2,125 | $96.87 | A | 48,824 | D | |
| Common Stock | Apr 26, 2018 | M | 51,000 | $109.14 | A | 99,824 | D | |
| Common StockF2,F6 | Apr 26, 2018 | S | 53,125 | $160.12 | D | 46,699 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to BuyF7 | $77.31 | Apr 25, 2018 | M | 4,250 | D | — | Feb 4, 2024 | Common Stock | 4,250 | 0 | D |
| Stock Option (Right to BuyF8 | $91.05 | Apr 25, 2018 | M | 2,156 | D | — | Feb 1, 2026 | Common Stock | 2,156 | 17,241 | D |
| Stock Option (Right to BuyF9 | $86.52 | Apr 25, 2018 | M | 7,766 | D | — | Feb 2, 2027 | Common Stock | 7,766 | 23,299 | D |
| Stock Option (Right to BuyF10 | $96.87 | Apr 26, 2018 | M | 2,125 | D | — | Jul 14, 2024 | Common Stock | 2,125 | 2,125 | D |
| Stock Option (Right to BuyF11 | $109.14 | Apr 26, 2018 | M | 51,000 | D | — | Feb 2, 2025 | Common Stock | 51,000 | 17,000 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 07/15/2014.
- F11The option vests in 16 quarterly installments from 02/03/2015.
- F2Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $154.98 (range $154.32 to $155.31).
- F4Open market sales reported on this line occurred at a weighted average price of $155.62 (range $155.32 to $156.29).
- F5Open market sales reported on this line occurred at a weighted average price of $156.78 (range $156.38 to $157.29).
- F6Open market sales reported on this line occurred at a weighted average price of $160.12 (range $160.00 to $160.23).
- F7Fully vested.
- F8The option vests in 16 quarterly installments from 02/02/2016.
- F9The option vests in 16 quarterly installments from 02/03/2017.